多發性中風失智症市場規模、佔有率和成長分析：按診斷、治療、藥物類別、最終用戶、分銷管道和地區分類 - 行業預測，2026-2033年

2024 年全球多發性梗塞性失智症市場價值為 26.8 億美元，預計到 2025 年將成長至 28.6 億美元，到 2033 年將成長至 48.5 億美元，在預測期（2026-2033 年）內複合年成長率為 6.8%。

全球多發性梗塞性失智症市場涵蓋藥物、診斷和護理服務，旨在緩解與多發性梗塞相關的血管性失智症，這種疾病約佔全球失智症病例的20%。高血壓和糖尿病等心血管危險因子的日益普遍導致中風率上升，從而推動了市場成長。近期研究揭示了中風發病率的上升趨勢，促使保險公司和政府加大對早期檢測的投入。各公司正積極回應，加強研發，尤其是在標靶缺血通路神經保護劑方面。人工智慧驅動的自動化技術催生了先進的神經影像學和生物標記工具，徹底革新了診斷領域，實現了梗塞相關病變的早期檢測。這項創新提高了治療反應率，吸引了對個人化失智症照護的投資，並促使政府調整報銷政策。

多發性梗塞性失智症的全球市場促進因素

全球預期壽命的延長導致老年人口不斷成長，而老年人本身就更容易患上血管疾病，進而引發多次中風。隨著越來越多的人超過通常失智症中風高危險年齡層的人群，發生多次中風的可能性也隨之增加，從而導致對診斷、治療和長期護理的需求日益成長。為此，醫療機構正在提升服務水平，製藥公司和醫療設備製造商也加大研發投入，推動市場成長。這一持續趨勢也促使政策制定者加大對預防措施的投入，進而增強了市場實力。

全球多發性梗塞性失智症市場面臨的限制因素

由於先進診斷工具和專業治療方案的高成本，全球多發性梗塞性失智症市場面臨許多限制因素。這種經濟負擔對醫療服務提供者和患者都造成了影響，使得許多患者難以獲得必要的治療。不同地區不完善的保險報銷系統加劇了這個問題，迫使醫療機構選擇更經濟的治療方案。這種經濟障礙限制了相關產品和服務的普及，尤其是在中低收入地區，經濟拮据嚴重影響醫療決策。此外，持續的看護者支持也增加了治療的總成本，阻礙了市場更廣泛的滲透。

全球多發性中風失智症市場趨勢

在先進神經影像生物標記整合的推動下，全球多發性梗塞性失智症市場正經歷重大變革。臨床醫生擴大採用彌散張量成像（DTI）和功能性磁振造影（fMRI）等先進技術，以早期檢測提示認知功能徵兆的血管病變。這一趨勢不僅有助於臨床試驗中的早期診斷和患者分層，還能根據個別病變特徵制定個人化治療性介入。對提高預後預測準確性的關注正在促進合作研究網路的形成，這些網路推動了通用影像方案的製定，從而使科學進步能夠迅速融入全球醫療保健系統的日常臨床實踐。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球多發性梗塞性失智症市場規模：依診斷分類

• 神經影像學
• 認知功能評估
• 臨床試驗

全球多發性梗塞性失智症市場規模：依治療方法分類。

• 藥物治療
• 認知復健
• 支持性護理

全球多發性梗塞性失智症市場規模：依藥物類別分類

• 膽鹼酯酶抑制劑
• NMDA受體拮抗劑
• 抗高血壓藥物

全球多發性梗塞性失智症市場規模：依最終用戶分類

• 醫院
• 神經科診所
• 長期照護機構

全球多發性梗塞性失智症市場規模：按分銷管道分類

• 醫院藥房
• 零售藥房
• 網路藥房

全球多發性梗塞性失智症市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Eisai Co., Ltd.
• Pfizer Inc.
• Novartis AG
• AbbVie Inc.
• Otsuka Holdings Co., Ltd.
• Lundbeck A/S
• Takeda Pharmaceutical Company Limited
• Johnson & Johnson
• Merck & Co., Inc.
• Roche Holding AG
• Biogen Inc.
• Eli Lilly and Company
• Bristol Myers Squibb Company
• Amgen Inc.
• Sanofi SA
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Dr. Reddy's Laboratories Ltd.
• Sun Pharmaceutical Industries Limited
• Zydus Lifesciences Limited

結論與建議

Global Multi-Infarct Dementia Market size was valued at USD 2.68 Billion in 2024 and is poised to grow from USD 2.86 Billion in 2025 to USD 4.85 Billion by 2033, growing at a CAGR of 6.8% during the forecast period (2026-2033).

The Global Multi-Infarct Dementia Market encompasses drugs, diagnostics, and care services aimed at mitigating vascular dementia linked to multiple infarcts, a condition representing around 20% of global dementia cases. The escalating prevalence of cardiovascular risk factors like hypertension and diabetes contributes to increased cerebral infarction rates, driving market growth. Recent studies reveal a rise in incidence, leading insurers and governments to invest in early-detection initiatives. Companies are responding with intensified R&D efforts, particularly in neuroprotective agents targeting ischemic pathways. The advent of advanced neuroimaging and biomarker tools, enabled by AI-driven automation, has revolutionized diagnostics, allowing for earlier identification of infarct-related pathologies. This innovation enhances therapeutic responsiveness and attracts investment in personalized dementia care, prompting regulatory adjustments in reimbursement policies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Multi-Infarct Dementia market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Multi-Infarct Dementia Market Segments Analysis

Global multi-infarct dementia market is segmented by diagnosis, treatment, drug class, end user, distribution channel and region. Based on diagnosis, the market is segmented into Neuroimaging, Cognitive Assessment and Laboratory Testing. Based on treatment, the market is segmented into Drug Therapy, Cognitive Rehabilitation and Supportive Care. Based on drug class, the market is segmented into Cholinesterase Inhibitors, NMDA Receptor Antagonists and Antihypertensive Agents. Based on end user, the market is segmented into Hospitals, Neurology Clinics and Long-Term Care Facilities. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Multi-Infarct Dementia Market

The increasing global life expectancy contributes to a growing elderly population, which is inherently more susceptible to vascular injuries that can result in multi-infarct dementia. As more individuals surpass the typical ages associated with stroke risk, the likelihood of experiencing multiple cerebral infarctions rises, leading to a heightened need for diagnostic, therapeutic, and long-term care options. In response, healthcare providers enhance their service offerings, while pharmaceutical and device manufacturers ramp up their research and development efforts, driving market growth. This ongoing trend also prompts policymakers to invest more resources into preventive initiatives, thereby bolstering overall market dynamics.

Restraints in the Global Multi-Infarct Dementia Market

The Global Multi-Infarct Dementia market faces significant constraints due to the high costs associated with advanced diagnostic tools and specialized treatment protocols. These financial burdens impact both healthcare providers and patients, making it challenging for many to access necessary care. In various areas, inadequate reimbursement systems exacerbate the issue, leading healthcare institutions to favor more affordable treatment options. This economic obstacle restricts the uptake of relevant products and services, particularly in low- and middle-income regions where budget limitations heavily influence healthcare decisions. Furthermore, the requirement for continuous support for caregivers adds to the overall costs of treatment, hindering broader market adoption.

Market Trends of the Global Multi-Infarct Dementia Market

The Global Multi-Infarct Dementia market is experiencing a significant transformation driven by the integration of advanced neuroimaging biomarkers. Clinicians are increasingly adopting sophisticated techniques, such as diffusion tensor imaging and functional MRI, to detect vascular lesions indicative of cognitive decline at earlier stages. This trend not only enhances early diagnosis and patient stratification for clinical trials but also enables personalized therapeutic interventions tailored to individual lesion profiles. The focus on improving prognostic accuracy is fostering collaborative research networks that promote shared imaging protocols, thereby expediting the incorporation of scientific advancements into everyday clinical practice across global healthcare systems.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Multi-Infarct Dementia Market Size by Diagnosis & CAGR (2026-2033)

• Market Overview
• Neuroimaging
• Cognitive Assessment
• Laboratory Testing

Global Multi-Infarct Dementia Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Drug Therapy
• Cognitive Rehabilitation
• Supportive Care

Global Multi-Infarct Dementia Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Cholinesterase Inhibitors
• NMDA Receptor Antagonists
• Antihypertensive Agents

Global Multi-Infarct Dementia Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Neurology Clinics
• Long-Term Care Facilities

Global Multi-Infarct Dementia Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Multi-Infarct Dementia Market Size & CAGR (2026-2033)

• North America (Diagnosis, Treatment, Drug Class, End User, Distribution Channel)
  • US
  • Canada
• Europe (Diagnosis, Treatment, Drug Class, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Diagnosis, Treatment, Drug Class, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Diagnosis, Treatment, Drug Class, End User, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Diagnosis, Treatment, Drug Class, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Eisai Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Holdings Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lundbeck A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations